BE903369A - Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten - Google Patents
Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten Download PDFInfo
- Publication number
- BE903369A BE903369A BE2/60807A BE2060807A BE903369A BE 903369 A BE903369 A BE 903369A BE 2/60807 A BE2/60807 A BE 2/60807A BE 2060807 A BE2060807 A BE 2060807A BE 903369 A BE903369 A BE 903369A
- Authority
- BE
- Belgium
- Prior art keywords
- water
- amino acids
- cis
- pharmaceutical preparations
- soluble pharmaceutical
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 18
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000004475 Arginine Substances 0.000 claims abstract description 7
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 abstract description 13
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 3
- 239000004472 Lysine Substances 0.000 abstract description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 229960003104 ornithine Drugs 0.000 abstract description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- -1 phosphomycin arginine salt Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65502—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
- C07F9/65505—Phosphonic acids containing oxirane groups; esters thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH4792/84A CH660306A5 (de) | 1984-10-05 | 1984-10-05 | Wasserloesliche pharmazeutische zusammensetzungen auf der basis von salzen der (-)cis-1,2-epoxypropylphosphonsaeure mit aminosaeuren. |
Publications (1)
Publication Number | Publication Date |
---|---|
BE903369A true BE903369A (nl) | 1986-02-03 |
Family
ID=4282621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2/60807A BE903369A (nl) | 1984-10-05 | 1985-10-04 | Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten |
Country Status (11)
Country | Link |
---|---|
JP (1) | JPS62223121A (it) |
KR (1) | KR860003012A (it) |
AT (1) | AT383736B (it) |
BE (1) | BE903369A (it) |
CH (1) | CH660306A5 (it) |
DE (1) | DE3535356A1 (it) |
ES (1) | ES8609351A1 (it) |
FR (1) | FR2571255B1 (it) |
GB (1) | GB2165152B (it) |
IT (1) | IT1201479B (it) |
NL (1) | NL8502712A (it) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH310498A (de) * | 1951-11-14 | 1955-10-31 | Waldhof Zellstoff Fab | Verfahren zur Stabilisierung von Alkalisalzen von Adenosinpolyphosphorsäuren. |
DE1767212B1 (de) * | 1967-04-13 | 1971-05-06 | Sumitomo Chemical Co | Verfahren zur Herstellung injizierbarer Arzneimittel |
US3639590A (en) * | 1967-07-25 | 1972-02-01 | Merck & Co Inc | Antibacterial composition containing (-) (cis-1 2-epoxypropyl) phosphoric acid |
BE756953A (fr) * | 1969-10-02 | 1971-04-01 | Merck & Co Inc | Potentialisation d'antibiotiques |
IT1161974B (it) * | 1978-02-02 | 1987-03-18 | Italchemi Spa | Derivti dell acido cis.i 2 epossipropilfosfonico loro procedimento di preparazione e composizioni farmaceutiche che li contengono |
DE2813814A1 (de) * | 1978-03-31 | 1979-10-18 | Boehringer Mannheim Gmbh | Hochwirksame, enteral resorbierbare pharmazeutische praeparate |
IT1112282B (it) * | 1978-07-19 | 1986-01-13 | Zambon Spa | Bis-(2-ammonio-2-idrossimetil-1,3-propandiolo)(2r-cis)-(3-metilossiranil)fosfonato |
IT1097578B (it) * | 1978-07-31 | 1985-08-31 | Italchemi Spa | Metodo per la preparazione di sali dell'acido (-) |
US4235900A (en) * | 1978-11-15 | 1980-11-25 | E. R. Squibb & Sons, Inc. | Cephradine compositions |
-
1984
- 1984-10-05 CH CH4792/84A patent/CH660306A5/de not_active IP Right Cessation
-
1985
- 1985-10-02 JP JP60219969A patent/JPS62223121A/ja active Pending
- 1985-10-03 AT AT0287185A patent/AT383736B/de not_active IP Right Cessation
- 1985-10-03 DE DE19853535356 patent/DE3535356A1/de not_active Withdrawn
- 1985-10-04 GB GB08524550A patent/GB2165152B/en not_active Expired
- 1985-10-04 NL NL8502712A patent/NL8502712A/nl not_active Application Discontinuation
- 1985-10-04 ES ES547625A patent/ES8609351A1/es not_active Expired
- 1985-10-04 BE BE2/60807A patent/BE903369A/nl not_active IP Right Cessation
- 1985-10-04 IT IT22367/85A patent/IT1201479B/it active
- 1985-10-05 KR KR1019850007328A patent/KR860003012A/ko not_active IP Right Cessation
- 1985-10-07 FR FR8514800A patent/FR2571255B1/fr not_active Expired
Also Published As
Publication number | Publication date |
---|---|
ATA287185A (de) | 1987-01-15 |
FR2571255B1 (fr) | 1988-09-16 |
KR860003012A (ko) | 1986-05-19 |
GB8524550D0 (en) | 1985-11-06 |
IT1201479B (it) | 1989-02-02 |
DE3535356A1 (de) | 1986-04-24 |
IT8522367A0 (it) | 1985-10-04 |
NL8502712A (nl) | 1986-05-01 |
JPS62223121A (ja) | 1987-10-01 |
ES8609351A1 (es) | 1986-09-01 |
GB2165152B (en) | 1988-03-16 |
FR2571255A1 (fr) | 1986-04-11 |
CH660306A5 (de) | 1987-04-15 |
GB2165152A (en) | 1986-04-09 |
ES547625A0 (es) | 1986-09-01 |
AT383736B (de) | 1987-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4049802A (en) | Zinc sulfadiazine and its use in the treatment of burns | |
US6337094B1 (en) | Aqueous solution for the parenteral nutrition | |
US4352814A (en) | Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs | |
JPH06507382A (ja) | 鎌状赤血球症の治療における分子矯正法 | |
US6242492B1 (en) | N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid in iron chelating therapy | |
EP0868425B1 (de) | Phospholipid-derivate von phosphonocarbonsäuren, deren herstellung sowie deren verwendung als antivirale arzneimittel | |
Drell et al. | Production of pantothenic acid deficiency syndrome in mice with ω-methylpantothenic acid | |
US5116949A (en) | Benzoyl urea compound-albumin complex | |
BE903369A (nl) | Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten | |
BE903368A (nl) | Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten | |
JPS60202822A (ja) | 抗ウイルス薬 | |
JPS6335635B2 (it) | ||
DE2820794C2 (de) | Salze der (-Hcis)-l^-Epoxypropylphosphonsäure, Verfahren zu ihrer Herstellung und diese enthaltendes pharmazeutisches Präparat | |
JPS6048925A (ja) | 安定なs−アデノシル−l−メチオニン塩を含有する注射可能な治療用組成物 | |
JP3854326B2 (ja) | コラゲナーゼ阻害剤 | |
EP0030023A3 (en) | A heterocyclic compound and its synthesis, pharmaceutical formulations thereof and the use of the compounds and the formulations in medicine | |
NZ205587A (en) | Composition comprising undecylenic acid for treating herpes simplex i | |
JPH07215868A (ja) | 細胞内グルタチオンを刺激する方法及び組成物 | |
KR960015953B1 (ko) | 피부에 축적하는 외용의 항바이러스성 약학적 조성물 및 그 제조방법 | |
CN1190581A (zh) | 复方利福平注射液 | |
JP3000490B2 (ja) | 抗白癬菌剤 | |
JP2893807B2 (ja) | アズレン誘導体含有液剤 | |
JPS5936615A (ja) | 発がん予防剤 | |
DE2609147A1 (de) | Propionsaeuresalze basischer aminosaeuren | |
JP2002505257A (ja) | ベンゾイルフェニル尿素を含む殺菌剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CH | Change of patent owner |
Owner name: *ISTITUTO GENTILI S.P.A. Effective date: 19851004 |
|
CA | Change of address of the owner of the patent |
Owner name: *ISTITUTO GENTILI S.P.A.VIA MAZZINI 112, PISA Effective date: 19860110 |
|
CH | Change of patent owner |
Owner name: *ISTITUTO GENTILI S.P.A. Effective date: 19860110 |
|
RE | Patent lapsed |
Owner name: ISTITUTO GENTILI S.P.A. Effective date: 19881031 |